Skip to Content
Merck
  • The Explorer study: the first double-blind RCT to assess the efficacy of TLC-NOSF on DFUs.

The Explorer study: the first double-blind RCT to assess the efficacy of TLC-NOSF on DFUs.

Journal of wound care (2013-05-15)
D R Shanahan
PMID23665662
ABSTRACT

Urgo Medical recently announced the launch of the Explorer study, a large, Europe-wide, clinical study on the efficacy and tolerability of UrgoStart Contact, a lipidocolloid technology dressing impregnated with nano-oligosaccharide factor, in the treatment of diabetic foot ulceration. The number of patients, investigating centres and countries involved, as well as the length of treatment and patient follow-up, make this an ambitious, double-blind, randomised controlled trial.

MATERIALS
Product Number
Brand
Product Description
419281
Sigma-Aldrich
Sodium carboxymethyl cellulose, average Mw ~250,000, degree of substitution 1.2
419338
Sigma-Aldrich
Sodium carboxymethyl cellulose, average Mw ~700,000
419273
Sigma-Aldrich
Sodium carboxymethyl cellulose, viscosity 50-200 cP , c=4% H2O at 25­°C
419311
Sigma-Aldrich
Sodium carboxymethyl cellulose, average Mw ~250,000, degree of substitution 0.7
C9481
Sigma-Aldrich
Carboxymethylcellulose sodium, meets USP testing specifications, Medium viscosity
419303
Sigma-Aldrich
Sodium carboxymethyl cellulose, average Mw ~250,000, degree of substitution 0.9
21904
Sigma-Aldrich
Carboxymethylcellulose sodium salt, ultra high viscosity, highly purified
21902
Sigma-Aldrich
Carboxymethylcellulose sodium salt, medium viscosity
C5013
Sigma-Aldrich
Carboxymethylcellulose sodium salt, High viscosity
C4888
Sigma-Aldrich
Carboxymethylcellulose sodium salt, Medium viscosity
C5678
Sigma-Aldrich
Carboxymethylcellulose sodium salt, low viscosity